Raj Manchanda, PhD 

Chief Technical Officer Advisor

Dr. Manchanda joins APIE-Therapeutics as Chief Technical Officer Advisor to lead and further advance the CMC & supply chain aspects for the Idiopathic Pulmonary Fibrosis (IPF) and Heart Failure (HF) therapies from pre-clinical into Clinical Trials.   Dr. Manchanda is the  Chief Technical Operations Officer (CTOO) at Anokion and leads all aspects of the company’s CMC, quality and drug supply activities. Raj brings over 23 years of pharmaceutics development and program management experience to Anokion and most recently was Innovation Portfolio Leader at the Bill & Melinda Gates Medical Research Institute. Previously, he was Chief Development Officer at Frequency Therapeutics where he had oversight of drug development and manufacturing, portfolio and project management, infrastructure-building, and execution of global clinical development and regulatory strategy. Prior to Frequency, Raj was Vice President, Neurodegeneration and Early-Stage Therapeutics Asset Development at Biogen. While at Biogen, he was instrumental in leading the CMC development for approval and commercialization for Tecfidera™. Earlier in his career, Raj held leadership positions in at Diatide, Avid Radiopharmaceuticals, Perkin Elmer Life and Analytical Sciences and URL Pharmaceuticals. During his 23 years in the pharmaceutical industry, he has worked on over 25 INDs and 6 NDAs, including two drug development programs that received Fast Track designation from the U.S. Food and Drug Administration. Raj received his Ph.D. in Chemistry from Yale University and was an Anna Fuller postdoctoral fellow at MIT.


Raj has also completed the Advanced Management Program from the Sloan School of Management at MIT. 

© 2020 by Apie Therapeutics. 

  • LinkedIn